The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Phase I/II BRUIN study: can pirtobrutinib maintain disease stability in R/R follicular lymphoma?
Nirav Niranjan Shah, MD, Medical College of Wisconsin, Milwaukee, WI, discusses results from the Phase I/II BRUIN study (NCT03740529) of pirtobrutinib, a noncovalent BTK inhibitor, in relapsed/refractory (R/R) follicular lymphoma. Dr Shah explains that pirtobrutinib was generally safe and well tolerated, with some patients achieving disease stabilization despite a relatively short median progression-free survival. He also highlights the drug’s potential role in preserving disease control and quality of life, particularly for patients who are older or frail and may benefit from a convenient oral treatment option. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
